| Publication date | Communities | Collections | Article title | Author(s) | Journal/Conference |
|---|---|---|---|---|---|
| 28 May 2019 | BMRC | Bioinformatics Institute | Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer | Denis M. Collins, Neil T. Conlon, Srinivasaraghavan Kannan, Chandra S. Verma, Lisa D. Eli, Alshad S. Lalani, John Crown | Cancers |
| 5 Aug 2015 | BMRC | p53 Laboratory | A Search for Synergy in the Binding Kinetics of Trastuzumab and Pertuzumab Whole and F(ab) to Her2 | Wai-Heng Lua, Samuel Ken-En Gan, David Philip Lane, Chandra Shekhar Verma | NPJ Breast Cancer |